|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.10 / 0.19|
Gains by Cephalon and Genzyme help boost the Amex biotech index. Amylin shares fall 1.7% after talks about pancreatitis and diabetes drug Byetta.
Shares of Medivation surge after announcing a major marketing deal with Pfizer.
The drugmaker is the latest to go shopping in a deal-happy summer.
If Roche is serious about buying the company, it will need to do much better than $89 a share.
Why Titan Pharma needs a development partner. And disparate outlooks for Gilead, Vanda and YM BioSciences.
Stocks in the sector are trading higher Friday, following a mysterious final-hour bludgeoning Thursday that left many in the red.
The chairman is opposed to the takeover bid and questions how much Bristol knew of ImClone's potential plan to split.
The trading panel had differing opinions about where this oil giant is going.
ImClone says it's 'studying the situation' after receiving a $60-per-share bid from Bristol-Myers.
Dour GDP and employment reports kept stocks down Thursday, with all three major indices closing in the red. Hear David Peltier, Dan Fitzpatrick, Robert Holmes and Adam Feuerstein give their takes on what moved the market.
The stock soars well above the $60 that Bristol-Myers is offering.
The sector is trading higher on today's buyout bid. One analyst offers a list of who else could tie the knot in the drug and biotech space.
ImClone shares are soaring on news of the $4.5 billion cash bid.
Last week's conference call did nothing to assure investors that the gene therapy drug for head and neck cancer can secure regulatory approval.
More discussion of Sangamo's SB-509, revisiting Delcath and questioning YM Bio's chances with nimo.
Maxygen slides on news Amgen was granted a patent that may affect Maxygen's MAXY-G34, a possible treatment for chemotherapy-induced neutropenia.
The first post-ASCO mailbag includes questions on ImClone, Peregrine, GenVec, Ariad and more.
The attention paid to Erbitux misses a large factor in the lung cancer realm.
Patients with a normal KRAS gene benefit the most from Erbitux plus chemo. But those with a mutated form of the gene receive no benefit from the ImClone drug.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.